Lipoprotein lipase compensates for the defective function of apo E variants in vitro by interacting with proteoglycans and lipoprotein receptors

Atherosclerosis

Volumn 145, Issue 1, 1999, Pages 61-69

  Mann, W Alexander ^a   Meyer, N ^a   Berg, D ^a   Greten, H ^a   Beisiegel, U ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Apolipoprotein E; Lipoprotein lipase; Lipoprotein receptors; Proteoglycans; Type III hyperlipoproteinemia

Indexed keywords

APOLIPOPROTEIN E; CHYLOMICRON; HEPARIN LYASE; LIPOPROTEIN LIPASE; LIPOPROTEIN RECEPTOR; PROTEOGLYCAN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; CELL TYPE; CHO CELL; ENZYME BINDING; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPOPROTEINEMIA; LIPOPROTEIN METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

ANIMALS; APOLIPOPROTEINS E; CHO CELLS; CHYLOMICRONS; CRICETINAE; FIBROBLASTS; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; PROTEOGLYCANS; RECEPTORS, LIPOPROTEIN;

EID: 0033049968     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00015-5     Document Type: Article

References (46)

1. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
2. Utermann G., Hees M., Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature. 269:1977;604-607.
3. Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochim. Biophys. Acta. 1005:1989;239-244.
4. Smit M., Knijff P.de, der Kooij-Meijs E.van, Groenendijk C., van den Maagdenberg A.M.J.M., Gevers Leuven J.A., Stalenhoef A.F.H., Stuyt P.M.J., Frants R.R., Havekes L.M. Genetic heterogeneity in familial dysbetalipoproteinema. The E2(lys146→gln) variant results in a dominant mode of inheritance. J. Lipid Res. 31:1990;45-53.
5. Horie Y., Fazio S., Westerlund J.R., Weisgraber K.H., Rall S.C. Jr. The functional characteristics of human apolipoprotein E variant (Cystein at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J. Biol. Chem. 267(3):1992;1962-1968.
6. Santamarina-Fojo S., Dugi K.A. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr. Opin. Lipidol. 5:1994;117-125.
7. Babirak S.P., Iverius P.H., Fujimoto W.Y., Brunzell J.D. Detection and characterization of heterozygous state for lipoprotein lipase deficiency. Arteriosclerosis. 9:1989;326-334.
8. Wilson D.E., Hata A., Kwong L.K., Lingam A., Shuhua J., Ridinger D.N., Yeager C., Kaltenborn K.C., Iverius P.H., Lalouel J.M. Mutations in exon 3 of the lipoproteine lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes. J. Clin. Invest. 92:1993;203-211.
9. Babirak S.P., Brown B.G., Brunzell J.D. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler. Thromb. 13:1992;804-814.
10. Ma Y., Ooii T.C., Liu M.S., Zhang H., Mc Pherson R., Edwards A., Forsythe I., Frohlich J., Brunzell J., Hayden M. High frequency of mutations in the human lipoprotein lipase gene in pregnancy induced chylomicronemia: possible association with apolipoprotein E2 isoform. J. Lipid Res. 35:1994;1066-1075.
11. Mann W.A., Meyer N., Weber W., Rinninger F., Greten H., Beisiegel U. Apolipoprotein E and lipoprotein lipase co-ordinately enhance binding and uptake of chylomicrons by human hepatozytes. Eur. J. Clin. Invest. 25:1995;880-882.
12. Steinmetz A., Assefbarkhi N., Eltze C., Ehlenz K., Funke H., Pies A., Assmann G., Kaffarnik H. Normolipemic dysbetalipo-proteinemia and hyperlipoproteinemia type III in subjects homozygous for a rare genetic apolipoprotein E variant (apoE1). J. Lipid Res. 31:1990;1005-1013.
13. Mann W.A., Lohse P., Gregg R.E., Ronan R., Hoeg J.M., Zech L.A., Brewer H.B. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of Apo E-1(Lys146→Glu). J. Clin. Invest. 96:1995;1100-1107.
14. Lohse P., Mann W.A., Stein E.A., Brewer H.B. Jr. Apolipoprotein E-4Philadelphia (Glu13→Lys, Arg145→Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. J. Biol. Chem. 266:1991;10479-10484.
15. Beil F.U., Fojo S.S., Brewer H.B. Jr., Greten H., Beisiegel U. Apolipoprotein C-II deficiency syndrome due to apoC-II Hamburg: clinical and biochemical features and HphI restriction enzyme polymorphisms. Eur. J. Clin. Invest. 22:1992;88-95.
16. Kovanen P.T., Brown M.S., Basu S.K., Bilheimer D.W., Goldstein J.L. Saturation and suppression of hepatic lipoprotein receptors: a mechanism for the hypercholesterolemia of cholesterol-fed rabbits. Proc. Natl. Acad. Sci. USA. 78:1981;1396-1400.
17. McFarlane A.S. Efficient trace labeling of proteins with iodine. Nature. 182:1958;53-54.
18. Zannis V.I. Genetic polymorphism in human apolipoprotein E. Methods Enzymol. 128:1986;823-851.
19. Hobbs H.H., Brown M.S., Russell D.W., Davignon J., Goldstein J.L. Deletion in the gene for the low-density lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 317:1987;734-737.
20. Esko J.D., Weinke J.L., Taylor W.H., Ekborg G., Roden L., Anantharamaiah G., Gawish A. Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galaktosyltransferase I. J. Biol. Chem. 262(25):1987;12189-12195.
21. Mann W.A., Meyer N., Weber W., Meyer S., Greten H., Beisiegel U. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and heparin reflects severity of associated type III hyperlipoproteinemia. J. Lipid Res. 36:1995;517-525.
22. Beisiegel U., Weber W., Olivecrona-Bengtsson G. Lipoprotein Lipase enhances the binding of chylomicrons to low density lipoprotein-receptor related protein. Proc. Natl. Acad. Sci. USA. 88:1991;8342-8346.
23. Lookene A., Skottova N., Olivecrona G. Interactions of lipoprotein lipase with the active site inhibitor tetrahydrolipstatin (Orlistat®). Eur. J. Biochem. 222:1994;395-403.
24. Goldstein J.L., Brown M.S. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J. Biol. Chem. 249:1974;5153-5162.
25. Ji Z.-S., Brecht W.J., Miranda R.D., Hussain M.M., Innerarity T.L., Mahley R.W. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268:1993;10160-10167.
26. Yanagishita M., Hascall V.C. Cell surface heparan sulfate proteoglycans. J. Biol. Chem. 267:1992;9451-9454.
27. Lilly-Stauderman M., Brown T.L., Balasubramaniam A., Harmony J.A.K. Heparin releases newly synthesized cell surface-associated apolipoprotein E from HepG2 cells. J. Lipid Res. 34:1993;190-200.
28. Williams K.J., Fless G.M., Petrie K.A., Snyder M.L., Brocia R.W., Swenson T.L. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein (a), low density lipoprotein, and nascent lipoproteins. J. Biol. Chem. 267:1992;13284-13292.
29. Obunike J.C., Edwards I.J., Rumsey S.C., Curtiss L.K., Wagner W.D., Deckelbaum R.J., Goldberg I.J. Cellular differences in lipoprotein lipase-mediated uptake of low density lipoproteins. J. Biol. Chem. 269:1994;13129-13135.
30. Eisenberg S., Sehayek E., Olivecrona T., Vlodavsky I. Lipoprotein Lipase enhances binding of lipoproteins to heparan sulfate on cell surface and extracellular matrix. J. Clin. Invest. 90:1992;2013-2021.
31. Kowal R.C., Herz J., Goldstein J.L., Esser V., Brown M.S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apolipoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86:1989;5810-5814.
32. Kowal R.C., Herz J., Weisgraber K.H., Mahley R.W., Brown M.S., Goldstein J.L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265(18):1990;10771-10779.
33. Bohnet K., Pillot T., Visvikis S., Sabolovic N., Siest G. Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J. Lipid Res. 37:1996;1316-1324.
34. Rensen C.N., van Berkel T.J.C. Apolipoprotein E effectively inhibits lipoprotein-lipase mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J. Biol. Chem. 271(25):1996;14791-14799.
35. Beisiegel U., Weber W., Ihrke G., Herz J., Stanley K.K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 341:1989;162-164.
36. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J., Yamamoto T. Rabbit very low density lipoprotein receptor: a low low density receptor like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. USA. 89:1992;9252-9256.
37. Willnow T.E., Goldstein J.L., Orth K., Brown M.S., Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J. Biol. Chem. 267(36):1992;26172-26180.
38. Takahashi S., Suzuki J., Kohno M., Oida K., Tamai T., Miyabo S., Yamamoto T., Nakai T. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J. Biol. Chem. 270(26):1995;15747-15754.
39. Niemeyer A., Gavfels M., Heeren J., Meyer N., Angelin B., Beisiegel U. VLDL receptor mediates the uptake of human chylomicron remnants in vitro. J. Lipid Res. 37:1996;1733-1742.
40. Ji Z.-S., Fazio S., Lee Y.L., Mahley R.W. Secretion-capture role for apolipoprotein E in remnant metabolism involving cell surface heparan sulfate proteoglycans. J. Biol. Chem. 269(4):1994;2764-2772.
41. Ji Z.S., Sanan D.A., Mahley R.W. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J. Lipid Res. 36:1995;583-592.
42. van Barlingen H.H.J.J., de Jong H., Erkelens D.W., de Bruin T.W.A. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apoliprotein C. J. Lipid Res. 37:1996;754-763.
43. Zhang H., Reymer P.W.A., Liu M.-S., Forsythe J., Groenemeyer B.E., Frohlich J., Brunzell J.D., Kastelein J.P., Hayden M.R., Ma Y. Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have an increased frequency of an Asn 291→Ser mutation in the human LPL gene. Arterioscler. Thromb. Vasc. Biol. 15:1995;1695-1703.
44. Jeppesen J., Hollenbeck C.B., Zhou M.-Y., Coulston A.M., Jones C., Chen Y.-D.I., Reaven G.M. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity and postprandial lipemia. Arterioscler. Thromb. Vasc. Biol. 15:1995;320-324.
45. de Man F.H.A.F., de Beer F., van der Laarse A., Smelt A.H.M., Gevers Leuven J.A., Havekes L.M. Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase. Atherosclerosis. 136:1998;255-262.
46. Salah D., Bohnet K., Gueguen R., Siest G., Visvikis S. Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J. Lipid Res. 38:1997;904-912.